ArticleBreast care (Basel, Switzerland)2025
Three-Fraction External Beam Radiotherapy in Patients with Early Breast Cancer.
Article in Breast care (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Late cardiac effects in patients with left breast cancer treated with hypofractionated radiotherapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients with early breast cancer (EBC) can be treated with accelerated partial breast irradiation (APBI). The objective of this study was to determine if a three-fraction APBI schedule is feasible for these patients. Methods: This single-institutional, phase 2 study included patients with age ≥45 years, tumor size <3.5 cm, negative nodes, negative surgical margins, and unicentric tumors. Patients were treated with 3D-CRT technique with a dose of 22.5 Gy in 3 fractions on 3 consecutive days. The primary end point of the study was cosmesis as assessed by physicians at 3 years. Secondary end points were cosmesis as assessed by patients, dosimetry, acute and late toxicities, disease-free and overall survival. Results: From October 2019 to October 2022, 49 patients were treated. Mean age of the patients was 55 years (range 40-75). At 3 years, physician- and patient-reported cosmetic results were excellent/good/fair in 33 (67%)/14 (29%)/2 (4%) of patients and in 29 (59%)/16 (33%)/4 (8%) of patients, respectively. Acute dermatitis grades 1 and 2 were observed in 14 (29%) and 3 (6%) of patients, respectively. At 6 months, breast edema, skin induration, subcutaneous fibrosis, pain, and pigmentation were observed in 3 (6%), 6 (12%), 3 (6%), 2 (4%), and 8 (16%) of patients, respectively. At 3 years, 1 (2%) patient had mild pain; no breast edema, skin induration, subcutaneous fibrosis, or pigmentation was observed. At a median follow-up of 39 months (range 24-60), there were no local/regional recurrences. One patient developed distant metastases in the bones, liver, and lungs at 46 months. All patients were alive at last follow-up. Conclusion: In patients with EBC, three-fraction APBI is feasible. Physician- and patient-reported cosmesis was excellent/good in 96% and 92% of patients, respectively. Late effects were only grade 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.